⑸　契約書作成の要否　要。
⑹　落札者の決定方法　本公告に示した物品を納入できると学長が判断した入札者であって、国立大学法人新潟大学契約事務取扱規程第11条の規定に基づいて作成された予定価格の制限の範囲内で最低価格をもって有効な入札を行った入札者を落札者とする。ただし、落札者となるべき者の入札価格によっては、その者により当該契約の内容に適合した履行がなされないおそれがあると認められるとき、又はその者と契約を締結することが公正な取引の秩序を乱すこととなるおそれがあって著しく不適当であると認められるときは、予定価格の制限の範囲内の価格をもって入札した次順位者を落札者とする。
⑺　手続における交渉の有無　無。
⑻　その他　詳細は、入札説明書による。なお、入札説明書等で当該調達に関する環境上の条件を定めた調達であると示されている場合は、十分理解した上で応札すること。

5　Summary
⑴　Official in charge of disbursement of the procuring entity : Sugata Takahashi, President, National University Corporation Niigata University
⑵　Classification of the products to be procured : 4
⑶　Nature and quantity of the products to be purchased :
A　Abatacept (Genetical Recombination) (250mg／vial) 600 vials
B　Dolutegravir Sodium Abacavir Sulfate Lamivudine (30tablets／vial) 100 vials
C　Riociguat (1mg 100tablets／case) 200 cases
D　Pembrolizumab (Genetical Recombination) (100mg 4ml／vial) 500 vials
E　Macitentan (10mg 30tablets／case) 100 cases
F　Osimertinib Mesilate (80mg 14tablets／case) 300 cases
G　Durvalumab (Genetical Recombination) (500mg 10mL／vial) 100 vials
H　Benralizumab (Genetical Recombination) (30mg 1mL／syringe) 100 syringes
I　Olaparib (150mg 56tablets／case) 100 cases
J　Palivizumab (Genetical Recombination) (100mg 1ml／vial) 200 vials
K　Asfotase Alfa (Genetical Recombination) (40mg 1ml／vial) 200 vials
L　Asfotase alfa (Genetical Recombination) (80mg 0.8ml／vial) 80 vials
M　Eculizumab (Genetical Recombination) (300mg 30ml／vial) 100 vials
N　Adalimumab (Genetical Recombination) (40mg 0.4ml／syringe) 1,000 syringes
O　Eribulin Mesilate (1mg 2ml／vial) 400 vials
P　Agalsidase beta (Genetical Recombination) (35mg／vial) 100 vials
Q　Agalsidase beta (Genetical Recombination) (5mg／vial) 200 vials
R　Lenalidomide Hydrate (5mg 40capsules／case) 100 cases
S　Canakinumab (Genetical Recombination) (150mg 1ml／vial) 20 vials
T　Eftrenonacog Alfa (Genetical Recombination) (3,000IU／ial (with solution)) 70 vials
U　Cetuximab (Genetical Recombination) (100mg 20ml／vial) 1,000 vials
V　Ustekinumab (Genetical Recombination) (45mg 0.5ml／syringe) 100 syringes
W　Pegfilgrastim (Genetical Recombination) (3.6mg 0.36ml／syringe) 500 syringes
X　Aflibercept (Genetical Recombination) (2mg 0.05ml／vial) 400 vials
Y　Nivolumab (Genetical Recombination) (240mg 24mL／vial) 700 vials
Z　Tazobactam Piperacillin Hydrate (4.5g 10vials／case) 2,000 cases
AA　Paclitaxel (100mg／vial) 1,000 vials
AB　Palonosetron hydrochloride (0.75mg 50m l5bags／case) 600 cases
AC　Denosumab (Genetical Recombination) (120mg 1.7ml／vial) 900 vials
AD　Bevacizumab (Genetical Recombination) (400mg 16ml／vial) 1,000 vials
AE　Pertuzumab (Genetical Recombination) (420mg 14ml／vial) 500 vials
AF　Tocilizumab (Genetical Recombination) (162mg 0.9ml／kit) 2,000 kits
AG　Atezolizumab (Genetical Recombination) (1,200mg 20ml／vial) 80 vials
AH　Tocilizumab (Genetical Recombination) (200mg 10ml／vial) 1,000 vials
AI　Bevacizumab (Genetical Recombination) (100mg 4ml／vial) 1,000 vials
AJ　Trastuzumab (Genetical Recombination) (150mg／vial(with solution)) 800 vials
AK　Rituximab (Genetical Recombination) (500mg 50ml／vial) 200 vials
AL　Elvitegravir Cobicistat Emtricitabine Tenofovir alafenamide fumarate (30 tablets／vial) 200 vials
AM　Infliximab (Genetical Recombination) (100mg／vial) 2,000 vials
AN　Ganciclovir (500mg／vial) 2,000 vials
AO　Golimumab (Genetical Recombination) (50mg 0.5ml／syringe) 200 syringes
AP　Pemetrexed Sodium Hydrate (500 mg／vial) 200 vials
AQ　Pemetrexed Sodium Hydrate (100 mg／vial) 700 vials
AR　Paclitaxel (30mg 5ml／vial) 8,000 vials
AS　Glatiramer Acetate (20mg 1ml 7 syringe／case) 1,000 cases
AT　Freeze-dried polyethylene glycol treated human normal immunoglobulin (5g／vial (with soluation)) 1,000 vials
AU　Brentuximab Vedotin (Genetical Recombination) (50mg／vial) 80 vials
AV　Panitumumab (Genetical Recombination) (100mg 5ml／vial) 400 vials
AW　Leuprorelin Acetate (11.25mg／syringe) 400 syringes
⑷　Delivery period : From 1 April, 2020 through 31 March, 2021
⑸　Delivery place : Niigata University Medical and Dental Hospital
⑹　Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A　not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B　have the Grade A or Grade B qualification during fiscal 2020 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C　prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D　prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,
E　meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,
F　not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.
⑺　Time limit of tender : 17 : 15　12 March, 2020
⑻　Contact point for the notice : Yukiyo Aoyama, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951―8520 Japan, TEL 025―227―2430
⑼　Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.